MaxCyte stock rallies on initial Q3 revenue, higher FY26 outlook

What happened: MaxCyte (MXCT) shares surged after the company reported preliminary third-quarter 2026 revenue growth and raised its full-year revenue guidance. Key numbers: Shares rose about 30.15% to roughly $1.26. Preliminary Q3 core business revenue rose 26% year over year to about $8.1M. Why it matters: The stock rally followed the preliminary revenue growth and the higher full-year outlook, signaling a positive market reaction to the raised guidance. Coverage: 3 outlets in 24h

MaxCyte (MXCT) shares surged after the company reported preliminary third-quarter 2026 revenue growth and raised its full-year revenue guidance.

The stock rally followed the preliminary revenue growth and the higher full-year outlook, signaling a positive market reaction to the raised guidance.